Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.

Goland S, Naugolny V, Korbut Z, Rozen I, Caspi A, Malnick S.

Eur J Intern Med. 2011 Aug;22(4):424-7. doi: 10.1016/j.ejim.2011.04.008. Epub 2011 May 31.

PMID:
21767763
2.

The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.

Shah KB, Rao K, Sawyer R, Gottlieb SS.

J Am Coll Cardiol. 2005 Sep 6;46(5):845-9.

3.

How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D.

J Card Fail. 2004 Aug;10(4):297-303.

PMID:
15309695
4.

Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.

Tamirisa KP, Aaronson KD, Koelling TM.

Am Heart J. 2004 Dec;148(6):971-8.

PMID:
15632880
5.

Safety of spironolactone use in ambulatory heart failure patients.

Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P.

Clin Cardiol. 2008 Nov;31(11):509-13. doi: 10.1002/clc.20284.

8.
9.

Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.

Cruz CS, Cruz AA, Marcílio de Souza CA.

Nephrol Dial Transplant. 2003 Sep;18(9):1814-9.

PMID:
12937229
10.

Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.

Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, Burkard T, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF Investigators.

Am J Cardiol. 2012 Mar 1;109(5):693-8. doi: 10.1016/j.amjcard.2011.10.027. Epub 2011 Dec 5.

PMID:
22152974
11.

Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.

Cavallari LH, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD.

Pharmacotherapy. 2010 Jan;30(1):1-9. doi: 10.1592/phco.30.1.1.

PMID:
20030467
13.

Elderly heart failure patients with drug-induced serious hyperkalemia.

Vanpee D, Swine CH.

Aging (Milano). 2000 Aug;12(4):315-9.

PMID:
11073352
14.

Hyperkalemia during spironolactone use in patients with decompensated heart failure.

Lima MV, Ochiai ME, Cardoso JN, Morgado PC, Munhoz RT, Barretto AC.

Arq Bras Cardiol. 2008 Sep;91(3):177-82, 194-9. English, Portuguese.

15.

Is spironolactone safe for dialysis patients?

Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL.

Nephrol Dial Transplant. 2003 Nov;18(11):2364-8.

PMID:
14551367
16.

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.

N Engl J Med. 1999 Sep 2;341(10):709-17.

17.

New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.

Cruz CS, Cruz LS, Domingues GS, Souza CA.

Expert Opin Drug Saf. 2005 Jul;4(4):677-88. Review.

PMID:
16011447
18.

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM.

Circulation. 2005 Jul 5;112(1):39-47. Epub 2005 Jun 27.

19.

Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.

Witham MD, Gillespie ND, Struthers AD.

Br J Clin Pharmacol. 2004 Nov;58(5):554-7.

20.

Usefulness of spironolactone in a specialized heart failure clinic.

Sligl W, McAlister FA, Ezekowitz J, Armstrong PW.

Am J Cardiol. 2004 Aug 15;94(4):443-7.

PMID:
15325926

Supplemental Content

Support Center